NEW ALLIANCE BETWEEN CLARIVATE ANALYTICS AND BIOINFOGATE TO DELIVER SAFETY & TOXICITY INTELLIGENCE TO PHARMA AND HEALTHCARE RESEARCHERS AND DECISION MAKERS
Bioinfogate will cross-link the OFF-X translational safety intelligence portal with the Cortellis suite of solutions from Clarivate Analytics to enable enhanced insights for targets and drugs of interest
Philadelphia / Barcelona, February 28, 2019
Bioinfogate, a leading healthcare data science organization, today announced it has into a global agreement with Clarivate Analytics to cross-link the OFF-X safety intelligence portal with Cortellis preclinical intelligence. In addition, Clarivate will leverage its commercial footprint to expand OFF-X usage to life science professionals who are benefiting from Cortellis, its suite of life sciences data and analytics solutions. The agreement makes it easier for customers to integrate, access and apply toxicity and adverse events intelligence across all phases of drug research and development (R&D).
Toxicity and adverse events cause more than 30% of drugs to fail during the R&D process, which costs the industry approximately $35 billion each year. OFF-X is used across pharma and biotech organizations, in leading research centers and by regulatory bodies around the world, addressing the need for new approaches to enhance early safety assessments that can reduce patient burden and avoid costly failures. Updated daily, OFF-X enables safety liabilities to be monitored and anticipated across all phases of drug R&D.
In this partnership, both organizations have also agreed to identify, develop and deploy new capabilities, including additional platform cross-linking, content syndication, and API-enabled integration to ensure interopability. Cortellis drug and target ontologies are used within OFF-X to provide platform linkages, which pave the way for enhanced data delivery.
“We are pleased to partner with Clarivate Analytics to expand and accelerate the reach of our safety and toxicology data assets,” commented Josep Prous, Jr., Executive Director, Bioinfogate. “We look forward to expanding the OFF-X value proposition by giving researchers and regulators access to complementary data, analytics and insights in Cortellis.”
“Ensuring drug safety is of vital importance to our industry, and enabling the interoperability between Cortellis and the OFF-X platform will help to advance this goal,” said Mukhtar Ahmed, President, Life Sciences, Clarivate Analytics. “Through this partnership, we’ll be able to significantly expand the reach – and utility – of critical drug efficacy and safety information to researchers around the world.”
Bioinfogate is a forward-thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.
Our passion and capabilities stem from more than 60 years’ experience creating and managing biomedical knowledge, first at Prous Science (1958-2007, acquired by Thomson Reuters in 2007), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous Group of companies to embrace a long tradition and expertise in scientific knowledge management.
For more information visit www.bioinfogate.com
About Bioinfogate OFF-XTM
The Bioinfogate OFF-XTM portal provides integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of drug R&D, including first-in-class and emerging targets. OFF-X allows prompt identification of toxicology & safety signals and de-risking of R&D projects. As of February 2019, the portal covers a range of 15,000 targets and 10,000 drugs & biologics, and is populated with more than 260,000 expertly curated safety alerts and 500,000 references of interest associated to 4,000 adverse effects. OFF-X is used across pharma and biotech organizations, in leading research centers and regulatory bodies
For more information visit www.targetsafety.info
Cortellis gives life to science by unlocking the hidden insights in data. This industry-leading solution curates the broadest and deepest sources of intelligence to enable precise, actionable answers to specific questions across the R&D lifecycle — from discovery and clinical development through regulatory submission and commercialization. By supporting data-driven decisions, Cortellis helps pharmaceutical companies, biotech and medical device/diagnostic firms accelerate innovation. In 2017, 80% of U.S. companies filing NMEs, 91% of companies achieving breakthrough therapy status and 70% of the top licensing deals were informed by Cortellis intelligence.
To learn more, visit www.Clarivate.com/Cortellis
About Clarivate Analytics
Clarivate Analytics is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. Building on a heritage going back more than a century and a half, we have built some of the most trusted brands across the innovation lifecycle, including the Web of Science, Cortellis, Derwent, CompuMark, MarkMonitor and Techstreet. Today, Clarivate Analytics is a new and independent company on a bold entrepreneurial mission, to help our clients radically reduce the time from new ideas to life-changing innovations.
For more information, please visit www.clarivate.com.
This press release and oral statements made with respect to information contained in this release may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics’ current expectations or forecasts of future events and may include statements regarding anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics’ control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise.
Download this article Clarivate and Bioinfogate partnership agreeement PR 20190225